Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio in aperto per valutare la sicurezza e l'efficacia di CABA-201 in soggetti con miopatia infiammatoria idiopatica attiva

12 novembre 2026 aggiornato da: Cabaletta Bio

Uno studio di fase 1/2, in aperto, per valutare la sicurezza e l'efficacia delle cellule T autologhe del recettore chimerico specifico per l'antigene CD19 (CABA-201) in soggetti con miopatia infiammatoria idiopatica attiva

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.

Tipo di studio

Interventistico

Iscrizione (Stimato)

74

Fase

  • Fase 2
  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Göttingen, Germania, 37075
        • Non ancora reclutamento
        • Universitätsmedizin Göttingen - Accepting Adult Patients
        • Contatto:
        • Investigatore principale:
          • Dr. Jana Zschüntzsch
      • Roma, Italia, 00165
        • Reclutamento
        • Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Professor Franco Locatelli
      • London, Regno Unito, WC1N 3BG
        • Reclutamento
        • University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
        • Contatto:
        • Investigatore principale:
          • Dr. Pedro Machado, FRCP, PhD
      • London, Regno Unito, SE5 9RS
        • Reclutamento
        • Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
        • Contatto:
        • Investigatore principale:
          • Patrick Gordon, PhD, FRCP, MBBS
      • London, Regno Unito, WC1N 3JH
        • Reclutamento
        • Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Professor Despina Eleftheriou
      • Manchester, Regno Unito, M13 9WL
        • Reclutamento
        • Manchester Royal Infirmary - Accepting Adult Patients
        • Contatto:
        • Investigatore principale:
          • Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
      • Salford, Regno Unito, M6 8HD
        • Reclutamento
        • Salford Royal Hospital - Accepting Adult Patients
        • Contatto:
        • Investigatore principale:
          • Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
    • California
      • Orange, California, Stati Uniti, 92868
        • Reclutamento
        • University of California Irvine - Accepting Adult Patients
        • Investigatore principale:
          • Tahseen Mozaffar, MD
        • Contatto:
      • San Francisco, California, Stati Uniti, 94158
        • Reclutamento
        • University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Susan Kim, MD, MMSc
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80046
        • Reclutamento
        • Children's Hospital Colorado - Accepting Juvenile Patients
        • Investigatore principale:
          • Dr. Kentaro Yomogida, MD
        • Contatto:
    • Florida
      • Jacksonville, Florida, Stati Uniti, 32224
        • Reclutamento
        • Mayo Clinic Florida - Accepting Adult Patients
        • Contatto:
      • St. Petersburg, Florida, Stati Uniti, 33701
        • Reclutamento
        • Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
        • Investigatore principale:
          • Natalie Booth, DO
        • Contatto:
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30032
        • Reclutamento
        • Emory University - Accepting Adult Patients
        • Contatto:
        • Investigatore principale:
          • Prateek Chandrashekar Gandiga, MD, FACP
      • Atlanta, Georgia, Stati Uniti, 30029
        • Reclutamento
        • Children's Healthcare of Atlanta - Accepting Juvenile Patients
        • Investigatore principale:
          • Shanmuganathan Chandrakasan, MD
        • Contatto:
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Northwestern Memorial Hospital - Accepting Adult Patients
        • Investigatore principale:
          • Dr. George Georges, MD
        • Contatto:
      • Chicago, Illinois, Stati Uniti, 60637
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Pooja N. Patel, DO
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • Reclutamento
        • University of Kansas Medical Center - Accepting Adult Patients
        • Contatto:
    • Maryland
      • Bethesda, Maryland, Stati Uniti, 20892
        • Reclutamento
        • National Institutes of Health - Accepting Adult and Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Andrew Mammen, M.D., Ph.D.
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02115
        • Reclutamento
        • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
        • Investigatore principale:
          • Susan Prockop, MD
        • Contatto:
    • Michigan
      • Ann Arbor, Michigan, Stati Uniti, 48105
        • Reclutamento
        • University of Michigan - Accepting Young Adult and Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Dr. Jennifer Agrusa, MD
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55902
        • Reclutamento
        • Mayo Clinic - Accepting Adult Patients
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10021
        • Reclutamento
        • Hospital for Special Surgery - Accepting Adult and Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • David R. Fernandez, MD, PhD
      • New York, New York, Stati Uniti, 10021
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
        • Investigatore principale:
          • Jae Park, MD
        • Contatto:
      • The Bronx, New York, Stati Uniti, 10467
        • Reclutamento
        • Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Dr. Dawn Wahezi, MD, MS
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27599
        • Reclutamento
        • University of North Carolina at Chapel Hill - Accepting Adult Patients
        • Investigatore principale:
          • Saira Sheikh, MD
        • Contatto:
      • Durham, North Carolina, Stati Uniti, 27710
        • Reclutamento
        • Duke University Medical Center - Accepting Young Adults and Juvenile Patients
        • Investigatore principale:
          • Kaveh Ardalan, MD, MS
        • Contatto:
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Reclutamento
        • Oregon Health & Science University - Accepting Adult Patients
        • Contatto:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Dr. Caitlin Elgarten, MD, MSCE
      • Pittsburgh, Pennsylvania, Stati Uniti, 15261
        • Reclutamento
        • UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
        • Contatto:
        • Investigatore principale:
          • Jeremy Tilstra, MD
      • Pittsburgh, Pennsylvania, Stati Uniti, 15224
        • Reclutamento
        • UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Kathryn Torok, MD
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Reclutamento
        • Vanderbilt University Medical Center - Accepting Adult Patients
        • Contatto:
    • Texas
      • Dallas, Texas, Stati Uniti, 75390
        • Reclutamento
        • University of Texas Southwestern Medical Center - Accepting Juvenile Patients
        • Investigatore principale:
          • Samuel John, MD
        • Contatto:
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • Houston Methodist Hospital - Accepting Adult Patients
        • Contatto:
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • University of Texas MD Anderson Cancer Center - Accepting Adult Patients
        • Investigatore principale:
          • Huifang (Linda) Lu, MD
        • Contatto:
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84113
        • Reclutamento
        • Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Aimee Ogden Hersh, MD
    • Washington
      • Seattle, Washington, Stati Uniti, 98105
        • Reclutamento
        • Seattle Children's Research Institute - Accepting Juvenile Patients
        • Contatto:
        • Investigatore principale:
          • Dr. Susan Shenoi, MD, MS
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Non ancora reclutamento
        • Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
        • Investigatore principale:
          • Sara Sabbagh, DO
        • Contatto:
          • Erin Hammelev - Research Coordinator
          • Numero di telefono: 414-337-7064
          • Email: ehammele@mcw.edu

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 6 anni a 75 anni (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Adult Cohorts

Inclusion Criteria:

  • Age ≥18 and ≤75
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Diagnosis of DM, ASyS, or IMNM
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
  • Presence of muscle weakness

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Juvenile Cohort

Inclusion Criteria:

  • Age ≥6 and ≤17 years at enrollment
  • A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
  • Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography

Other protocol-defined criteria apply.

Exclusion Criteria:

  • Contraindication to leukapheresis
  • History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
  • Active infection requiring medical intervention at screening
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
  • Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
  • Significant lung or cardiac impairment
  • Previous CAR T cell therapy
  • Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant

Other protocol-defined criteria apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: CABA-201 Phase 1/2

DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM.

ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS.

IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Altri nomi:
  • Rese-Cel
  • Resecabtagene autoleucel
Sperimentale: CABA-201 Phase 2b - Sub-study 1

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Altri nomi:
  • Rese-Cel
  • Resecabtagene autoleucel
Sperimentale: CABA-201 Phase 2b - Sub-study 2

Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM.

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide

Altri nomi:
  • Rese-Cel
  • Resecabtagene autoleucel

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Phase 1/2: Incidence and severity of adverse events (AEs)
Lasso di tempo: Up to 28 days after CABA-201 infusion

Incidence and severity of AEs

Up to 28 days after CABA-201 infusion
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Within 16 weeks

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 16 weeks
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Within 24 weeks

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Within 24 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of adverse events and laboratory abnormalities
Lasso di tempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Incidence and severity of AEs, including changes in laboratory values and vital signs

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacodynamics (PD)
Lasso di tempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of B cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Pharmacokinetics (PK)
Lasso di tempo: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)

Levels of CABA-201-positive T cells in the blood

Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
Change in disease-related biomarkers of muscle inflammation
Lasso di tempo: Up to 156 weeks (Phase 1/2)

Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum

Up to 156 weeks (Phase 1/2)
Change in autoantibody-related biomarkers
Lasso di tempo: Up to 156 weeks (Phase 1/2)

Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum

Up to 156 weeks (Phase 1/2)
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 16 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 16 (Sub-study 1)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 16 (Sub-study 1)
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 16 (Sub-study 1)

≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 16 (Sub-study 1)
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Lasso di tempo: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Lasso di tempo: Week 52 (Sub-study 1)

≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 1)
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 24 (Sub-study 2)

MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength

Week 24 (Sub-study 2)
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Lasso di tempo: Week 52 (Sub-study 2)

≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement

Week 52 (Sub-study 2)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Cattedra di studio: Medical Director, Cabaletta Bio

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 dicembre 2023

Completamento primario (Stimato)

1 luglio 2028

Completamento dello studio (Stimato)

1 luglio 2028

Date di iscrizione allo studio

Primo inviato

16 novembre 2023

Primo inviato che soddisfa i criteri di controllo qualità

30 novembre 2023

Primo Inserito (Effettivo)

4 dicembre 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .